The Korean drugmaker, which co-promotes Wegovy with Novo Nordisk locally, credits the obesity drug for operating profit of 23.7 billion won, though net profit fell.
Recap by typeshit. Full story at Chosunbiz.
Tara Wider has spent about five years posting on holistic beauty and women's wellness, building a following of women her age on social media.
Brown says diet and exercise still matter, but argues that shaming people for treating obesity with medication has never made anyone healthier.
A short share on growing GLP-1 use in the US, with no figures or sources attached. Thin on detail beyond the headline itself.
A new survey covered by Chain Store Age tracks how GLP-1 users are shifting their food spending from restaurants toward grocery stores.
On his podcast, the NHS GP cites studies suggesting hunger hormones rebound within weeks and that people regain about 60% of lost weight within a year.
Symphony Health data reported by Bloomberg shows Novo Nordisk's oral Wegovy climbing again in week 42, up from 208,304 the week before.
Loading…